Evexia Lifecare (524444)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Let me be candid: this is exactly the kind of stock that gets a value investor's pulse racing for all the wrong reasons. At ₹2.91, Evexia Lifecare trades at 176 times earnings, yet its return on equity is a paltry 0.28% and ROCE just 0.30%. If you handed me this business today, it earns almost nothing on the capital employed. The latest quarter tells the real story – ₹25 crore of sales, but net profit of precisely zero. That is not a business; it is a turnover story. The profit growth of 141.67% sounds impressive, but from a base of effectively nothing, any jitter in the numbers looks enormous. The sales growth of 16.31% is respectable, but for a chemical trader, that is hardly a moat. Book value per share is ₹1.55, so the market is paying nearly 1.9 times for a business earning 0.28% on that equity. The price has already run up from ₹0.47 to ₹2.91 – a six-fold jump – and even a generous PEG of 2.23 suggests the price has run far ahead of fundamentals. The Piotroski F-score of 7/9 shows some improving fundamentals, but for a pure trading business with no pricing power, that can reverse quickly. No dividend means we are relying entirely on price appreciation from other buyers – a greater fool theory. With promoter holding not disclosed, I have no assurance that those running the show have skin in the game. This is not investing; it is speculation. I would need a far lower price, evidence of sustainable margins, and serious capital allocation discipline before I would even look closer.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer